image credit: Pexels

Trial readout sets up filings for Insmed bronchiectasis drug

The phase 3 trial achieved a statistically significant reduction in the frequency of exacerbations in patients with bronchiectasis, a serious, chronic lung disease with no approved treatment that affects around a million people across the US, Europe, and Japan.

In bronchiectasis, the walls of the airways become thickened and damaged as a result of a cycle of inflammation and infections. It is characterised by repeated exacerbations or attacks, which require treatment with antibiotics and sometimes result in patients being hospitalised.

Read More on Pharmaphorum